


11/11/02  
Reg under  
1.114


<b>REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL</b> Address to: Commissioner for Patents Box RCE Washington, DC 20231	Application Number	09/847,935
	Filing Date	May 3, 2001
	First Named Inventor	Woodward
	Group Art Unit	1615
	Examiner Name	Fubara, B.M.
	Attorney Docket No.	D2914

Bet  
102802

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

<b>1. Submission required under 37 CFR 1.114</b>	
a. <input checked="" type="checkbox"/> Previously submitted	
i. <input checked="" type="checkbox"/> Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on <u>September 16, 2002</u> (Any unentered amendment(s) referred to above will be entered).	
ii. <input type="checkbox"/> Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____	
iii. <input type="checkbox"/> Other _____	
b. <input type="checkbox"/> Enclosed	
i. <input type="checkbox"/> Amendment/Reply	
ii. <input type="checkbox"/> Affidavit(s)/Declaration(s)	
iii. <input type="checkbox"/> Information Disclosure Statement (IDS)	
iv. <input type="checkbox"/> Other _____	
<b>2. Miscellaneous</b>	
a. <input type="checkbox"/> Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(f) required)	
b. <input type="checkbox"/> Other _____	
<b>3. Fees</b> The RCE fee under 37 CFR 1.17 (c) is required by 37 CFR 1.114 when the RCE is filed.	
a. <input checked="" type="checkbox"/> The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. <u>01-0885</u>	
i. <input checked="" type="checkbox"/> RCE fee required under 37 CFR 1.17(e)	
ii. <input type="checkbox"/> Extension of time fee (37 CFR 1.136 and 1.17)	
iii. <input type="checkbox"/> Other _____	
b. <input type="checkbox"/> Check in the amount of \$ _____ enclosed	
c. <input type="checkbox"/> Payment by credit card (Form PTO-2038 enclosed)	

<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED</b>			
Name (Print/Type)	Frank J. Uxa	Registration No. (Attorney/Agent)	25,612
Signature		Date	10/15/02

<b>CERTIFICATE OF MAILING OR TRANSMISSION</b>			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:			
Name (Print/Type)	Janet McGhee	Date	10/15/02
Signature		Date	10/15/02

BEST AVAILABLE COPY

Docket D-2914

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Woodward  
Serial No: 09/847,935  
Filed: May 3, 2001  
For: COMPOSITIONS HAVING  
ENHANCED PHARMACOKINETIC  
CHARACTERISTICS

Examiner: Fubara, B. M.

GAU: 1615

Box RCE  
Commissioner for Patents  
Washington, D.C. 20231

SECOND RESPONSE TO JULY 15, 2002 OFFICE ACTION

Dear Sir:

Please amend the above-identified application as follows:

In the Abstract:

Please replace the title of the Abstract with the following  
title:

COMPOSITIONS HAVING ENHANCED PHARMACOKINETIC CHARACTERISTICS

In the Claims:

Please cancel claim 42 without prejudice.

Please rewrite claims 36, 40, 41, 43-46, 48, 49, 51-53, 59,  
60, 63, and 64 as follows:

**BEST AVAILABLE COPY**